Renascience (TSE:4889) Other Current Liabilities: 円26.31 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4889 Renascience Inc TSE:4889
51 GF Score
Price 円1,148.00
GF Value 円305.40
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Renascience Other Current Liabilities?

Renascience TSE:4889 -6.67% 51 Other Current Liabilities is 円26.31 Mil as of Mar. 2026. GuruFocus rates TSE:4889 with a GF Score™ of 51/100 and a GF Value™ of 円305.40 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Renascience's other current liabilities for the quarter that ended in Mar. 2026 was 円26.31 Mil.

Renascience's quarterly other current liabilities declined from Sep. 2025 (円43.56 Mil) to Dec. 2025 (円43.53 Mil) and declined from Dec. 2025 (円43.53 Mil) to Mar. 2026 (円26.31 Mil).

Renascience's annual other current liabilities increased from Mar. 2024 (円2.58 Mil) to Mar. 2025 (円6.60 Mil) and increased from Mar. 2025 (円6.60 Mil) to Mar. 2026 (円26.31 Mil).

Renascience Other Current Liabilities Related Terms

Renascience Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Renascience's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Renascience Other Current Liabilities Chart

Renascience Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Liabilities
Get a 7-Day Free Trial 2.67 2.49 2.58 6.60 26.31

Renascience Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.28 43.56 43.53 26.31 5.56
TSE:4889
51GF Score
Renascience Inc TSE:4889
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Renascience Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of 円26.31 Mil mean?
Renascience (TSE:4889) has a Other Current Liabilities of 円26.31 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Renascience.
Is Renascience's Other Current Liabilities too high?
Renascience's current Other Current Liabilities is 円26.31 Mil. Overall, Renascience has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Renascience's Other Current Liabilities compare to ABT and SYK?
Renascience's Other Current Liabilities of 円26.31 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Devices & Instruments company?
A good Other Current Liabilities depends on the Medical Devices & Instruments industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Renascience. Renascience's current Other Current Liabilities is 円26.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renascience stock overvalued right now?
Based on GuruFocus' analysis, Renascience (TSE:4889) is currently considered Significantly Overvalued. The stock's GF Value™ is 円305.40, compared to a current price of 円1,148.00 — trading 275.9% above its estimated fair value. The current Other Current Liabilities is 円26.31 Mil. Renascience's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Renascience (TSE:4889), the current Other Current Liabilities is 円26.31 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Renascience (TSE:4889) Overvalued in 2026?

Based on GuruFocus' analysis, Renascience stock appears to be overvalued. The current stock price of 円1,148.00 is trading 275.9% above its estimated GF Value™ of 円305.40. GuruFocus considers Renascience to be Significantly Overvalued.

Key valuation signals for TSE:4889:

  • Other Current Liabilities: 円26.31 Mil
  • GF Value™: 円305.40 vs. price of 円1,148.00 (275.9% above fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the TSE:4889 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Renascience Business Description

Address 2-1 Seiryo-cho, Aoba-ku, Miyagi, Sendai, JPN, 103-0023
Renascience Inc is engaged in the Development and commercialization of pharmaceuticals, medical devices, pieces of software as a medical device (SaMD) utilizing AI, etc.
51GF Score

Get the complete analysis for TSE:4889

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,148.00
Price
円305.40
GF Value